- patients considered as inappropriate for this study for any reason like noncompliance by the researcher, - patients with persisting refractory nausea, vomiting, chronic diarrhoea or chronic gastrointestinal disorders, inability to swallow the study drug which may affect adequate absorption, - patients with chronic liver disease: alanine aminotransferase (alt)/aspartate aminotransferase (ast) elevated over 5 times the upper limit of normal (uln), - patients with gout or hyperuricemia (above the uln), - patients with severe pneumonia symptoms, - patients with known allergy to favipiravir or for substances used in the study, - patients did not receive specific antiviral drugs such as lopinavir/ritonavir, ribavirin, arbidol, chloroquine phosphate, hydroxychloroquine, and monoclonal antibodies within one week before admission. - patients with known chronic renal impairment/failure [creatinine clearance (cccl) <30 ml/min], - pregnant and lactating women - patients undergoing cardiac ablation therapy - patients using antiarrhythmic drugs - patients actively receiving chemotherapy - acute immunosuppressed patients - patients undergoing psychosis therapy

- patients considered as inappropriate for this study for any reason like noncompliance by the researcher, - patients with persisting refractory nausea, vomiting, chronic diarrhoea or chronic gastrointestinal disorders, inability to swallow the study drug which may affect adequate absorption, - patients with chronic liver disease: alanine aminotransferase (alt)/aspartate aminotransferase (ast) elevated over 5 times the upper limit of normal (uln), - patients with gout or hyperuricemia (above the uln), - patients with severe pneumonia symptoms, - patients with known allergy to favipiravir or for substances used in the study, - patients did not receive specific antiviral drugs such as lopinavir/ritonavir, ribavirin, arbidol, chloroquine phosphate, hydroxychloroquine, and monoclonal antibodies within one week before admission. - patients with known chronic renal impairment/failure [creatinine clearance (cccl) <30 ml/min], - pregnant and lactating women - patients undergoing cardiac ablation therapy - patients using antiarrhythmic drugs - patients actively receiving chemotherapy - acute immunosuppressed patients - patients undergoing psychosis therapy